Yahoo
NasdaqGS - Nasdaq Real Time Price USD

AngioDynamics, Inc. (ANGO)

12.40 +0.27 (+2.23%)
As of 11:42:56 AM EDT. Market Open.
Trade ANGO on Coinbase

Key Executives

Amounts are as of December 31, 2026 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. James C. Clemmer
CEO, President & Director 2.37M -- 1964
Mr. Stephen A. Trowbridge
Executive VP & CFO 1.11M -- 1974
Mr. Lawrence T. Weiss
Senior VP, Chief Legal Officer & Corporate Secretary 941.53k -- 1970
Mr. Warren G. Nighan
Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain 906.43k -- 1969
Ms. Laura Piccinini
Senior VP and GM of Cardiovascular & International 1.03M -- 1969
Mr. Saleem M. Cheeks
Vice President of Communications -- -- --
Mr. Benjamin H. Davis
Senior Vice President of Business Development & Strategy -- -- 1964
Ms. Marna I. Bronfen-Moore
Senior Vice President of Human Resources -- -- 1967
Mr. Chad T. Campbell
Senior VP and GM of Oncology & Interventional Devices 592.76k -- 1971
Ms. Kim L. Seabury
Senior Vice President of Information Technology -- -- 1967

AngioDynamics, Inc.

14 Plaza Drive
Latham, NY 12110
United States
518 795 1400 https://www.angiodynamics.com
Sector: 
Healthcare
Full Time Employees: 
632

Description

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Corporate Governance

AngioDynamics, Inc.’s ISS Governance QualityScore as of October 1, 2026 is 3. The pillar scores are Audit: 7; Board: 2; Shareholder Rights: 6; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

January 6, 2027 at 12:30 PM UTC

AngioDynamics, Inc. Earnings Date

Recent Events

October 8, 2026 at 12:00 AM UTC

DEFA14A: Proxy Statements

September 29, 2026 at 12:00 AM UTC

10-K/A: Periodic Financial Reports

July 14, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

April 23, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 2, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 3, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 14, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 6, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

November 12, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 21, 2025 at 12:00 AM UTC

S-8: Offering Registrations

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: